跳至主要内容
临床试验/NCT01909336
NCT01909336已完成3 期

Use of Isotonic Solutions Versus Hypotonic Solutions for Preventing Hospital Acquired Hyponatremia.

Instituto Tecnologico y de Estudios Superiores de Monterey0 个研究点目标入组 161 人开始时间: 2013年7月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
161
主要终点
Hospital Acquired Hyponatremia

研究概览

简要总结

The purpose of this study is to determine if isotonic solutions reduce the risk of hospital acquired hyponatremia compared with hypotonic solutions.

详细描述

Multicenter, Randomized, Controlled clinical trial.

The purpose of this study is to determine if isotonic solutions reduce the risk of hospital acquired hyponatremia compared with hypotonic solutions

This study will include 150 patients in 2 groups according to these type of pathology: group 1: medical conditions which includes respiratory problems (pneumonia, bronchiolitis, acute asthma attack) and acute gastrointestinal problems (bacterial or viral gastroenteritis) and group 2: surgical conditions (pre, peri or postoperative patients will be included). Each group will be randomized to receive 3 types of interventions: 0.3% Saline (hypotonic solution), 0.45% Saline (hypotonic solution) or 0.9% Saline (isotonic solution). In non-dehydrated patients the daily total volume of liquid infused will be determined by the volumetric Holliday- Segar* formula and the daily total volume will be calculated by adding the maintenance requirements (using the Holliday Segar formula) to the fluid deficit (according to percent of estimated weight**) in dehydrated patients.

The glucose concentrations in the first group will be 3.3%, and in group 2 and 3 will be 5%. The potassium concentration will be 20mEq/L in all groups. Blood samples will be collected before, 8 hours and 24 hours after the start of intravenous fluid, for the analysis of sodium, potassium, glucose, urea and creatinine. The adverse clinical outcomes at 8 and 24 hours of the start of intravenous fluid will also be recorded. The sodium plasma level, the incidence of hyponatremia and the adverse clinical outcomes will be compared.

*0-10 kilogram (kg): 100ml/kg per day; 10-20 kg: 1000 ml + 50 ml/kg/day over 10 kg; >20 kg: 1500 ml + 20ml/ kg over 20kg

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Care Provider, Investigator)

入排标准

年龄范围
3 Months 至 15 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Children between 3 months to 15 years.
  • Need for intravenous fluids for 8 hours or more.
  • Normal serum sodium at the beginning of the study of the study (135-145 mEQ/L).
  • Acute respiratory problems (acute asthma attack, bronchiolitis or pneumonia).
  • Acute gastrointestinal disorders (viral o bacterial gastroenteritis).
  • Elective surgical procedures.
  • Pre, peri o post operative patients (acute appendicitis, intussusception, intestinal perforation, ileus).

排除标准

  • Severe hyponatremia (serum sodium < 125 mEq/L).
  • Severe hypernatremia (serum sodium >155 mEq/L).
  • Need for intravenous fluids for less than 8 hours according with their treating physician.
  • Severe dehydration or Shock.
  • Preexisting chronic diseases (renal diseases, heart diseases or endocrine disorders).
  • Neurologic diseases.
  • Head trauma.
  • Cerebral edema or Intracranial hypertension.
  • Diabetic ketoacidosis.
  • Use of diuretics one week or less before the study.
  • Need for admission to the pediatric critical intensive care unit

研究组 & 干预措施

Group 1: 0.3% Saline in 3.3% dextrose (intravenous)

Active Comparator

Group 1: 0.3% Saline in 3.3% dextrose (intravenous)

干预措施: 0.3% Saline in 3.3% dextrose (Drug)

Group 2: 0.45% Saline in 5% dextrose (intravenous)

Active Comparator

Group 2: 0.45% Saline in 5% dextrose (intravenous)

干预措施: 0.45% Saline in 5% dextrose (Drug)

Group 3: 0.9% Saline in 5% dextrose (intravenous)

Active Comparator

Group 3: 0.9% Saline in 5% dextrose (intravenous)

干预措施: 0.9% Saline in 5% dextrose (Drug)

结局指标

主要结局

Hospital Acquired Hyponatremia

时间窗: 8 hours

Serum sodium less than 135 mEq/L at 8 hours in a patient with normal serum sodium (135 mEq/L to 145mEq/L) at the beginning of the study

次要结局

  • Dysnatraemias at T8(8 hours)
  • Adverse Reactions Attributed to Acute Plasma Sodium Changes(8 hours)

研究者

发起方
Instituto Tecnologico y de Estudios Superiores de Monterey
申办方类型
Other
责任方
Principal Investigator
主要研究者

Claudia Montserrat Flores Robles, MD

Claudia Montserrat Flores Robles

Instituto Tecnologico y de Estudios Superiores de Monterey

相似试验